A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry

Therapeutic Drug Monitoring

Volumn 20, Issue 1, 1998, Pages 1-6

  Bathum, Lise ^a   Hansen, Torben Stiig ^b   Hørder, Mogens ^b   Brøsen, Kim ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

CYP2C 19; Genetic polymorphism; Genotyping

Indexed keywords

HYDROLYASE; ISOENZYME; S MEPHENYTOIN HYDROLASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; ASIAN; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME POLYMORPHISM; GENE ISOLATION; GENOTYPE; HUMAN; ISOTOPE LABELING; OLIGONUCLEOTIDE PROBE; PRIORITY JOURNAL; RACE DIFFERENCE;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; DENMARK; EUROPEAN CONTINENTAL ANCESTRY GROUP; EUROPIUM; FEMALE; FLUOROMETRY; GENOTYPE; HUMANS; LANTHANUM; MALE; MIXED FUNCTION OXYGENASES; OLIGONUCLEOTIDE PROBES; PHENOTYPE; POLYMERASE CHAIN REACTION; SAMARIUM;

EID: 0031936795     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199802000-00001     Document Type: Article

References (25)

1. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver P450 2C19: correlation between 2C19 and S-mephenytoin 4′ hydroxylation. Arch Biochem Biophys 1993;306:240-5.
2. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-Mephenytoin 4′hydroxylase in humans. Biochemistry 1994;33:1743-52.
3. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur Clin Pharmacol 1990;39:533-7.
4. Drøhse A, Bathum L, Brøsen K, Gram LF. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 1989;27:620-5.
5. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985;19:483-7.
6. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarian proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1985;37:512-21.
7. Andersson T, Regårdh C, Dahl-Puustinen M, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12:415-6.
8. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not to debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
9. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
10. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-7.
11. Nielsen KK, Broøsen K, Hansen MG, Gram LF. Single dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-27.
12. Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992;52:350-8.
13. Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19,CYP2D6 and CYP1A2: a panel study. Clin Pharmacol Ther 1995;57:670-7.
14. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-Mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
15. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K. Identification of a new genetic defect responsible for the polymorphism of (S)-Mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
16. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5: 312-7.
17. Brøsen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993;36:105-8.
18. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metabolism Disp 1987;15:277-9.
19. Bliss C. Statistics in Biology. NY: McGraw Hill, 1967;348-403.
20. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996;6:521-6.
21. Dahlén P, Carlson J, Liukkonen L, et al. Europium-labeled oligonucleotides to detect point mutations: application to PI Z alpha-antitrypsin deficiency. Clin Chem 1993;39:1626-31.
22. Delahunty CM, Ankener W, Brainerd S, Nickerson DA, Mononen IT. Finnish-type aspartylglucosaminuria detected by oliginucleotide ligation assay. Clin Chem 1995;41:59-61.
23. Landegren U, Kaiser R, Sanders J, Hood L. A ligase-mediated gene detection technique. Science 1988;241:1077-80.
24. Samiotaki M, Kwiatkowsky M, Parik J, Landegren U. Dual-color detection of DNA sequence variants by ligase-mediated analysis. Genomics 1994;20:238-42.
25. Hansen TS, Petersen NE, Iitiä A, Blaabjerg O, Hyltoft-Petersen P, Hørder M. Robust nonradioactive oliginucleotide ligation assay to detect a common point mutation in the CYP2D6 gene causing abnormal drug metabolism. Clin Chem 1995;41:413-8.